Searched for
CIPLA STOCK DECLINE
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...11 Jun, 2026, 10.31 AM IST- Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...01 Jun, 2026, 01.12 PM IST
- Ahead of Market: 10 things that will decide stock market action on FridayBSE Sensex and Nifty 50 extended gains for a second session, led by banking, metal and pharma stocks despite IT weakness. Analysts flagged ...14 May, 2026, 10.31 PM IST
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...14 May, 2026, 11.04 AM IST
- Q4 earnings, crude oil, FII action among 8 factors to steer D-Street this weekIndian stock markets are set for a busy week. Key events like Q4 earnings announcements for many companies will influence trading. Foreign ...10 May, 2026, 09.39 AM IST
- LIC’s $2 billion contrarian bet: 10 stocks the DII giant bought while the market bledLife Insurance Corporation of India invested nearly $2 billion in 10 stocks during the March quarter's market fall. LIC bought shares in co...08 May, 2026, 09.46 AM IST
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...04 May, 2026, 06.00 AM IST
- Two Trades for Today: A pharma major for an 8.1% upmove, a mid-cap specialty chemical stock for a rise of about 6%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...26 Apr, 2026, 11.26 AM IST
- Most hated stocks: FIIs dumping these 146 companies without a break for 4 straight quarters. Do you own any?Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...24 Apr, 2026, 09.03 AM IST
- Pharma stocks buck market weakness as Dr Reddy's gainsPharma stocks showed strength on Thursday, defying market weakness. Dr Reddy's Laboratories saw significant gains, fueled by anticipation o...24 Apr, 2026, 05.29 AM IST
- Ahead of Market: 10 things that will decide stock market action on ThursdayNifty 50 and BSE Sensex declined, snapping a three-day rally due to IT and FMCG losses. Rising India VIX signaled caution, though broader t...22 Apr, 2026, 09.02 PM IST
- Cipla shares slide 5% after drug major's Q3 net profit drops 57% YoYCipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacted by a fall in gRevlimid sales. Re...23 Jan, 2026, 03.22 PM IST
- Analysts lower targets on CiplaThey were also disappointed with the margin guidance of 21-22% for the ongoing financial year. Shares of Cipla ended up 1.2% to close at ₹9...12 May, 2022, 06.28 AM IST
- Analysis: A tale of three pharma companies and a quarterCipla beat expectations riding the demand for Covid medication. The Street is likely to push the stock to its record high hit in 2015. Whil...10 Aug, 2020, 10.47 AM IST
- Centrum cuts target price for CiplaCipla's revenues during Q2FY19 declined 2% YoY while the margin was down by 220 bps.15 Nov, 2018, 04.12 PM IST
- Cipla and other pharma companies to have good times: P Phani Sekhar"Believers in Cipla can actually use this opportunity to accumulate the stocks more."08 Feb, 2013, 06.07 PM IST
- Pharmas are quite divided: Deepak Mohoni"Pharmas are quite divided. There are two very strong pharmas at the moment. They are Sun Pharma and Cipla. They are making all the moves."29 Nov, 2011, 05.01 PM IST
Load More
